Table 2 Antimicrobial susceptibility of Neisseria isolates cultured from the oropharynx of 64 STI clinic attendees (men who have sex with men) and 32 employees of the Institute of Tropical Medicine (representing the general population) in Belgium.
Prevalence (n/N) Participants (%) | Azithromycin (mg/L) Median (IQR) | Ciprofloxacin (mg/L) Median (IQR) | Ceftriaxone (mg/L) Median (IQR) | |
|---|---|---|---|---|
Pathogenic Neisseria spp. | 27/96 (28.1) | 0.5 (0.4–0.9) | 0.004 (0.003–0.006) | < 0.016 (< 0.016–< 0.016) |
Neisseria meningitidis | 26/96 (27.1) | 0.5 (0.3–0.9) | 0.004 (0.003–0.005) | < 0.016 (< 0.016–< 0.016) |
Employees | 2/32 (6.3) | 1.0 (0.8–1.3) | 0.065 (0.034–0.095) | < 0.016 (< 0.016–< 0.016) |
MSM who used AB previous 6 months | 9/32 (28.1) | 0.8 (0.5–1.5) | 0.004 (0.002–0.006) | < 0.016 (< 0.016–0.012) |
MSM who used no AB previous 6 months | 15/32 (46.9) | 0.5 (0.4–0.5) | 0.004 (0.003–0.004) | < 0.016 (< 0.016–< 0.016) |
Neisseria gonorrhoeae | 1/96 (1.0) | 0.125 | 2.0 | < 0.016 |
Employees | 0/32 (0.0) | – | – | – |
MSM who used AB previous 6 months | 0/32 (0.0) | – | – | – |
MSM who used no AB previous 6 months | 1/32 (3.1) | 0.125 | 2.0 | < 0.016 |
Non-pathogenic Neisseria spp. | 65/96 (67.7) | 3.0 (2.0–7.5) | 0.032 (0.016–0.25) | 0.047 (0.029–0.064) |
Employees | 32/32 (100.0) | 3.0 (2.0–4.0) | 0.023 (0.012–0.064) | 0.034 (0.026–0.064) |
MSM who used AB previous 6 months | 19/32 (59.4) | 16.0 (3.0–> 256.0) | 0.250 (0.141–0.500) | 0.047 (0.032–0.094) |
MSM who used no AB previous 6 months | 14/32 (43.8) | 4.0 (3.0–48.0) | 0.125 (0.016–0.380) | 0.047 (0.032–0.064) |
Neisseria subflava | 63/96 (65.6) | 3.5 (2.5–16.0) | 0.125 (0.016–0.380) | 0.047 (0.028–0.064) |
Employees | 31/32 (96.9) | 3.0 (2.3–4.0) | 0.032 (0.016–0.197) | 0.035 (0.028–0.052) |
MSM who used AB previous 6 months | 13/32 (40.6) | 288 (3.5–> 256.0) | 0.380 (0.190–0.500) | 0.064 (0.032–0.064) |
MSM who used no AB previous 6 months | 19/32 (59.4) | 4.0 (3.3–72.0) | 0.125 (0.022–0.380) | 0.047 (0.028–0.126) |
Neisseria mucosa | 14/96 (14.6) | 3.5 (2.3–5.5) | 0.016 (0.013–0.030) | 0.040 (0.032–0.064) |
Employees | 8/32 (25.0) | 3.5 (2.8–4.5) | 0.017 (0.011–0.025) | 0.040 (0.032–0.072) |
MSM who used AB previous 6 months | 4/32 (12.5) | 3.5 (2.8–6.3) | 0.133 (0.015–1.688) | 0.040 (0.032–0.051) |
MSM who used no AB previous 6 months | 2/32 (6.3) | 12.6 (6.9–18.3) | 0.016 (0.016–0.016) | 0.063 (0.048–0.079) |
Neisseria oralis | 8/96 (8.3) | 2.0 (1.9–3.1) | 0.015 (0.012–0.018) | 0.056 (0.032–0.064) |
Employees | 8/32 (25.0) | 2.0 (1.0–3.1) | 0.015 (0.012–0.018) | 0.056 (0.032–0.064) |
MSM who used AB previous 6 months | 0/32 (0.0) | – | – | – |
MSM who used no AB previous 6 months | 0/32 (0.0) | – | – | – |
Neisseria cinerea | 3/96 (3.1) | 2.0 (1.5–15.0) | 0.012 (0.009–0.022) | < 0.016 (< 0.016–< 0.016) |
Employees | 3/32 (9.4) | 2.0 (1.5–15.0) | 0.012 (0.009–0.022) | < 0.016 (< 0.016–< 0.016) |
MSM who used AB previous 6 months | 0/32 (0.0) | – | – | – |
MSM who used no AB previous 6 months | 0/32 (0.0) | – | – | – |
Neisseria elongata | 3/96 (3.1) | 0.5 (0.4–0.6) | 0.004 (0.004–0.014) | 0.047 (0.035–0.119) |
Employees | 3/32 (9.4) | 0.5 (0.4–0.6) | 0.004 (0.004–0.014) | 0.047 (0.035–0.119) |
MSM who used AB previous 6 months | 0/32 (0.0) | – | – | – |
MSM who used no AB previous 6 months | 0/32 (0.0) | – | – | – |
Neisseria lactamica | 2/96 (2.1) | 1.5 (1.3–1.8) | 0.127 (0.096–0.159) | < 0.016 (< 0.016–< 0.016) |
Employees | 2/32 (6.3) | 1.5 (1.3–1.8) | 0.127 (0.096–0.159) | < 0.016 (< 0.016–< 0.016) |
MSM who used AB previous 6 months | 0/32 (0.0) | – | – | – |
MSM who used no AB previous 6 months | 0/32 (0.0) | – | – | – |
Neisseria bacilliformis | 1/96 (1.0) | 2 (–) | 0.125 (–) | 1.5 (–) |
Employees | 1/32 (3.1) | 2 (–) | 0.125 (–) | 1.5 (–) |
MSM who used AB previous 6 months | 0/32 (0.0) | – | – | – |
MSM who used no AB previous 6 months | 0/32 (0.0) | – | – | – |
